A Trial of HTI-1090 in Subjects With Advanced Solid Tumors
A Phase I, Open-Label, Multicenter, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of HTI-1090 in Patients With Advanced Solid Tumors
Sponsor: Atridia Pty Ltd.
This PHASE1 trial investigates Advanced Solid Tumors and is currently completed. Atridia Pty Ltd. leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
Sep 2019 — Oct 2019 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
-
Dec 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Atridia Pty Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .